Nishikubo, H.; Kawabata, K.; Ma, D.; Sano, T.; Imanishi, D.; Sakuma, T.; Maruo, K.; Fan, C.; Yamamoto, Y.; Yashiro, M.
Optimal Cutoff Value of the Tumor Mutation Burden for Immune Checkpoint Inhibitors: A Lesson from 175 Pembrolizumab-Treated Cases Among 6403 Breast Cancer Patients. Appl. Sci. 2025, 15, 10173.
https://doi.org/10.3390/app151810173
AMA Style
Nishikubo H, Kawabata K, Ma D, Sano T, Imanishi D, Sakuma T, Maruo K, Fan C, Yamamoto Y, Yashiro M.
Optimal Cutoff Value of the Tumor Mutation Burden for Immune Checkpoint Inhibitors: A Lesson from 175 Pembrolizumab-Treated Cases Among 6403 Breast Cancer Patients. Applied Sciences. 2025; 15(18):10173.
https://doi.org/10.3390/app151810173
Chicago/Turabian Style
Nishikubo, Hinano, Kyoka Kawabata, Dongheng Ma, Tomoya Sano, Daiki Imanishi, Takashi Sakuma, Koji Maruo, Canfeng Fan, Yurie Yamamoto, and Masakazu Yashiro.
2025. "Optimal Cutoff Value of the Tumor Mutation Burden for Immune Checkpoint Inhibitors: A Lesson from 175 Pembrolizumab-Treated Cases Among 6403 Breast Cancer Patients" Applied Sciences 15, no. 18: 10173.
https://doi.org/10.3390/app151810173
APA Style
Nishikubo, H., Kawabata, K., Ma, D., Sano, T., Imanishi, D., Sakuma, T., Maruo, K., Fan, C., Yamamoto, Y., & Yashiro, M.
(2025). Optimal Cutoff Value of the Tumor Mutation Burden for Immune Checkpoint Inhibitors: A Lesson from 175 Pembrolizumab-Treated Cases Among 6403 Breast Cancer Patients. Applied Sciences, 15(18), 10173.
https://doi.org/10.3390/app151810173
